WBR0808: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 8: Line 8:
|MainCategory=Physiology
|MainCategory=Physiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|MainCategory=Physiology
|MainCategory=Physiology
|MainCategory=Physiology
|MainCategory=Physiology
|MainCategory=Physiology
Line 20: Line 21:
|MainCategory=Physiology
|MainCategory=Physiology
|SubCategory=Gastrointestinal
|SubCategory=Gastrointestinal
|Prompt=A researcher is studying the effect of a novel gastric inhibitory peptide (GIP) analog, GIP42, in mice.   He notes the plasma concentration of compound X following the oral intake of GIP42 in experiment 1 and following intravenous (I.V.) administration of GIP42 in experiment 2.  The graph below shows the evolution of plasma concentrations of compound X during both experiments.  Based on the researcher's findings, compound X most likely corresponds to which endogenous compound?
|Prompt=A researcher is studying the effect of a novel gastric inhibitory peptide (GIP) analog, GIP42, in mice. He follows the plasma concentration of compound X following the oral intake of GIP42 in experiment 1 and following intravenous (I.V.) administration of GIP42 in experiment 2.  The graph below demonstrates the evolution of plasma concentrations of compound X during both experiments.  Based on the researcher's findings, compound X most likely corresponds to which endogenous compound?
 
[[File:GIP graph.jpg|500px]]
|Explanation=Gastric inhibitory peptide (GIP), also known as glucose-dependent insulinotropic peptide is a GI hormone secreted by K cells in the duodenum and the jejunum.  GIP is considered an incretin, defined as having a role in insulin stimulation.  As such, oral GIP secretion following the oral intake of fatty acid, amino acids, and glucose, leads to an "incretin effect" due to the increased secretion of insulin following release of GIP in the GI tract.  The elevation in insulin levels is not seen in I.V. infusion of GIP.  As a result, "incretin effect" is seen following oral GIP but not I.V. GIP, which explains the variation in plasma concentration of compound X (insulin) during each experiment.
 
In addition to GIP, another incretin is GLP-1 (glucagon-like peptide-1) hormone.  Both incretins migrate in the circulation to the beta cells of the pancreas, their target cells to stimulate insulin secretion.  It has been postulated the incretin effect is defective in type 2 diabetes mellitus (T2DM); GLP-1 analogs are currently pharmacologic options for patients with T2DM


Educational Objective:
[[File:GIP graph.jpg|600px]]
Oral GIP intake or GIP secretion within the GI tract following a meal induces insulin secretion in a phenomenon called "incretin effect".
|Explanation=Gastric inhibitory peptide (GIP), also known as glucose-dependent insulinotropic peptide is a GI hormone secreted by K cells in the duodenum and the jejunum.  GIP is considered an incretin, i.e. a molecule that increases the amount of insulin released from pancreatic beta cells of the islets of Langerhans.  As such, oral GIP secretion following the oral intake of fatty acid, amino acids, and glucose, leads to an "incretin effect" due to the increased secretion of insulin following release of GIP in the GI tract.  The elevation in insulin levels is not seen in I.V. infusion of GIP.  As a result, "incretin effect" is seen following oral GIP but not I.V. GIP, which explains the variation in plasma concentration of compound X (insulin) during each experiment. In addition to GIP, another incretin is GLP-1 (glucagon-like peptide-1) hormone.  Both incretins migrate in the circulation to the beta cells of the pancreas, their target cells to stimulate insulin secretion.  It has been postulated the incretin effect is defective in type 2 diabetes mellitus (T2DM); GLP-1 analogs are currently pharmacologic options for patients with T2DM.
|AnswerA=Glucagon
|AnswerA=Glucagon
|AnswerAExp=GIP induces the secretion of insulin, not glucagon. GIP, glucagon, and secretin belong to the same family of hormones.
|AnswerAExp=GIP induces the secretion of insulin, not glucagon. GIP, glucagon, and secretin belong to the same family of hormones.
Line 37: Line 33:
|AnswerD=Secretin
|AnswerD=Secretin
|AnswerDExp=The main "incretin effect" is seen in insulin following GIP intake, not in secretin.  GIP, glucagon, and secretin belong to the same family of hormones.
|AnswerDExp=The main "incretin effect" is seen in insulin following GIP intake, not in secretin.  GIP, glucagon, and secretin belong to the same family of hormones.
|AnswerE=H+
|AnswerE=Hydrogen ions
|AnswerEExp=GIP inhibits the release of H+.
|AnswerEExp=GIP inhibits the release of H<sup>+</sup>.
|EducationalObjectives=Oral GIP intake or GIP secretion within the GI tract following a meal induces insulin secretion in a phenomenon called "incretin effect".
|RightAnswer=B
|RightAnswer=B
|WBRKeyword=insulin, incretin, effect, GLP-1, GLP, GIP, gastric, inhibitory, peptide, oral, iv, intravenous, i.v., intake, secretion, hormone, release, glucagon, acid, H+, secretin, diabetes, type, 2, type 2 diabetes, mellitus, type II diabetes,
|WBRKeyword=Insulin, Incretin effect, Incretins, GLP-1, GLP, GIP, Gastric inhibitory peptide, Hormone, Glucagon, Secretin, Diabetes, Type 2 diabetes mellitus,
|Approved=No
|Approved=Yes
}}
}}

Revision as of 20:19, 4 March 2015
Author [[PageAuthor::Rim Halaby, M.D. [1]]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Physiology
Sub Category SubCategory::Gastrointestinal
Prompt [[Prompt::A researcher is studying the effect of a novel gastric inhibitory peptide (GIP) analog, GIP42, in mice. He follows the plasma concentration of compound X following the oral intake of GIP42 in experiment 1 and following intravenous (I.V.) administration of GIP42 in experiment 2. The graph below demonstrates the evolution of plasma concentrations of compound X during both experiments. Based on the researcher's findings, compound X most likely corresponds to which endogenous compound?

]]

Answer A AnswerA::Glucagon
Answer A Explanation AnswerAExp::GIP induces the secretion of insulin, not glucagon. GIP, glucagon, and secretin belong to the same family of hormones.
Answer B AnswerB::Insulin
Answer B Explanation AnswerBExp::GIP secretion within the GI tract induces insulin secretion in a phenomenon called "incretin effect".
Answer C AnswerC::Motilin
Answer C Explanation AnswerCExp::A distinct relation between motilin and GIP is not established.
Answer D AnswerD::Secretin
Answer D Explanation AnswerDExp::The main "incretin effect" is seen in insulin following GIP intake, not in secretin. GIP, glucagon, and secretin belong to the same family of hormones.
Answer E AnswerE::Hydrogen ions
Answer E Explanation [[AnswerEExp::GIP inhibits the release of H+.]]
Right Answer RightAnswer::B
Explanation [[Explanation::Gastric inhibitory peptide (GIP), also known as glucose-dependent insulinotropic peptide is a GI hormone secreted by K cells in the duodenum and the jejunum. GIP is considered an incretin, i.e. a molecule that increases the amount of insulin released from pancreatic beta cells of the islets of Langerhans. As such, oral GIP secretion following the oral intake of fatty acid, amino acids, and glucose, leads to an "incretin effect" due to the increased secretion of insulin following release of GIP in the GI tract. The elevation in insulin levels is not seen in I.V. infusion of GIP. As a result, "incretin effect" is seen following oral GIP but not I.V. GIP, which explains the variation in plasma concentration of compound X (insulin) during each experiment. In addition to GIP, another incretin is GLP-1 (glucagon-like peptide-1) hormone. Both incretins migrate in the circulation to the beta cells of the pancreas, their target cells to stimulate insulin secretion. It has been postulated the incretin effect is defective in type 2 diabetes mellitus (T2DM); GLP-1 analogs are currently pharmacologic options for patients with T2DM.

Educational Objective: Oral GIP intake or GIP secretion within the GI tract following a meal induces insulin secretion in a phenomenon called "incretin effect".
References: ]]

Approved Approved::Yes
Keyword WBRKeyword::Insulin, WBRKeyword::Incretin effect, WBRKeyword::Incretins, WBRKeyword::GLP-1, WBRKeyword::GLP, WBRKeyword::GIP, WBRKeyword::Gastric inhibitory peptide, WBRKeyword::Hormone, WBRKeyword::Glucagon, WBRKeyword::Secretin, WBRKeyword::Diabetes, WBRKeyword::Type 2 diabetes mellitus
Linked Question Linked::
Order in Linked Questions LinkedOrder::
Retrieved from "https://www.wikidoc.org/index.php?title=WBR0808&oldid=1075080"